NeuralMed
About
NeuralMed uses AI to detect cancerous tumors in medical imaging with 97% accuracy, outperforming average radiologist reads. FDA 510(k) cleared for lung and breast cancer screening. Deployed at 45 hospitals across 12 states. $4.2M ARR with 120% net revenue retention.
AI Investment Summary
FDA-cleared AI cancer detection deployed at 45 hospitals. $4.2M ARR with 120% net revenue retention. Open to all investors at $250.
Structure
Reg CF Equity
Stage
Series A
Accreditation
Open to All
Liquidity
Illiquid
Geography
Boston, MA
Revenue
revenue generating
Funding Progress
64%Total Investors
2,800
Green Flags
- FDA 510(k) cleared
- $4.2M ARR with 120% NRR
- Deployed at 45 hospitals
- 97% detection accuracy
Risk Flags
- Regulatory risk — additional FDA clearances needed
- Competing with established medical imaging companies
- Healthcare sales cycles are long
- Reimbursement uncertainty
Similar Deals in Healthcare
DNA Chat (Mendly Care)
Seed
AI telemedicine + genome sequencing platform — $400 per genome.
Min. Investment
$100
Funded
25%
Breath Diagnostics
Seed
Detecting diseases with a single breath — non-invasive diagnostics.
Min. Investment
$100
Vybe Medical
Series A
AI-assisted mental health platform — $65/session, 25K patients.
Min. Investment
$200
Funded
58%
Minimum Investment
$250
Valuation
$55M
Lock-up Period
3+ years
Tags
LISTED
2026-01-05
ANNUAL REVENUE
$4.2M ARR